Increasing COVID-19 Trials is Offering an Opportunity for North American Monoclonal Antibodies Market

North American monoclonal antibodies market is estimated to grow at a CAGR of 6.8% during the forecast period. An increasing trial of monoclonal antibodies for COVID-19 has been reported in the region. As per the National Institutes of Health (NIH), monoclonal antibodies could act as vital components for the response to the COVID-19 outbreak till vaccines become available as it may provide short-term protection from SARS-CoV-2. In August 2020, GlaxoSmithKline plc and Vir Biotechnology, Inc. declared the first dose in phase II/III study with VIR-7831 (also referred to as GSK4182136). It is a completely human anti-SARS-CoV-2 monoclonal antibody (Severe Acute Respiratory Syndrome coronavirus-2). This is indicated for the early treatment of COVID-19 among patients at high risk of hospitalization. 

Browse the full report description North American Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Source (Murine, Chimeric, Human, and Humanized), By Application (Cancer, Infectious Diseases, Auto-Immune Diseases, Inflammatory Diseases, and Others) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/north-american-monoclonal-antibodies-market

Additionally, in August 2020, the National Institutes of Health (NIH) introduced a clinical trial that aims to test antibody therapy in hospitalized COVID-19 patients. Under the trial, COVID-19 patients at selected hospitals can volunteer in a clinical trial intended to test the efficacy and safety of an effective novel treatment for COVID-19. It is a Phase 3 randomized, controlled trial which is referred to as ACTIV-3, and as a master protocol. This is designed to test several diverse kinds of monoclonal antibody therapies. 

Scope of the North American Monoclonal Antibodies Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Source and Application
• Regions Covered- US and Canada
• Competitive Landscape- Amgen Inc., Eli Lilly & Co., Pfizer Inc., Merck & Co., Inc., and F. Hoffman La-Roche AG

Recent Strategic Initiatives in the North American Monoclonal Antibodies Market

• In December 2019, Mylan N.V. and Biocon Ltd. declared the US FDA launch of Ogivri (trastuzumab-dkst). It is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer. 
• In January 2020, Pfizer launched three new biosimilars named rituximab-pvvr (Ruxience), trastuzumab-qyyp (Trazimera), and bevacizumab-bvzr (Zirabev) in the US. This is expected that the specialty drugs will be launched at the lowest wholesale acquisition cost (WAC) among trastuzumab, bevacizumab, or rituximab products currently on the market. These drugs will become available at a discounted price than their equivalents brand name. This launch can support significant savings for the healthcare system in the US while enhancing access to vital therapies. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

North American Monoclonal Antibodies Market-Segmentation

By Source

• Murine
• Chimeric
• Human
• Humanized

By Application

• Cancer
• Infectious Diseases
• Auto-Immune Diseases
• Inflammatory Diseases
• Others

North American Monoclonal Antibodies Market– Segment by Country

• US
• Canada